Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats

W (Willem) Huisman; Eefje Schrauwen; Suzan Pas; Geert Amerongen; Guus Rimmelzwaan; Ab Osterhaus

doi:10.1016/j.vaccine.2008.03.023

Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats

W (Willem) Huisman, Eefje Schrauwen, Suzan Pas, Geert Amerongen, Guus Rimmelzwaan, Ab Osterhaus

Virology

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

Abstract

For the development of feline immunodeficiency virus (FIV) vaccines mostly structural proteins have been evaluated for their capacity to induce protective immunity. In the present study, subunit vaccines containing recombinant FIV accessory proteins Rev and OrfA were evaluated in cats. Cats were vaccinated repeatedly with these proteins, adjuvanted with immune stimulating complexes (ISCOMs). In addition, cats were vaccinated with bacterially expressed fragments spanning the entire FIV envelope protein, either atone or in combination with the regulatory proteins. Subsequently, the cats were challenged with a homologous FIV strain to assess the level of protective immunity achieved with the respective vaccination regimens. Although the vaccines proved to be immunogenic, vaccinated cats were not protected from infection with FIV. (C) 2008 Elsevier Ltd. All rights reserved.

Original language	Undefined/Unknown
Pages (from-to)	2553-2561
Number of pages	9
Journal	Vaccine
Volume	26
Issue number	21
DOIs	https://doi.org/10.1016/j.vaccine.2008.03.023
Publication status	Published - 2008

Research programs

EMC MM-04-27-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2008.03.023

http://hdl.handle.net/1765/29546

Cite this

@article{88ba5f3d1e87489794d013dec647099d,

title = "Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats",

abstract = "For the development of feline immunodeficiency virus (FIV) vaccines mostly structural proteins have been evaluated for their capacity to induce protective immunity. In the present study, subunit vaccines containing recombinant FIV accessory proteins Rev and OrfA were evaluated in cats. Cats were vaccinated repeatedly with these proteins, adjuvanted with immune stimulating complexes (ISCOMs). In addition, cats were vaccinated with bacterially expressed fragments spanning the entire FIV envelope protein, either atone or in combination with the regulatory proteins. Subsequently, the cats were challenged with a homologous FIV strain to assess the level of protective immunity achieved with the respective vaccination regimens. Although the vaccines proved to be immunogenic, vaccinated cats were not protected from infection with FIV. (C) 2008 Elsevier Ltd. All rights reserved.",

author = "Huisman, {W (Willem)} and Eefje Schrauwen and Suzan Pas and Geert Amerongen and Guus Rimmelzwaan and Ab Osterhaus",

year = "2008",

doi = "10.1016/j.vaccine.2008.03.023",

language = "Undefined/Unknown",

volume = "26",

pages = "2553--2561",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "21",

}

TY - JOUR

T1 - Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats

AU - Huisman, W (Willem)

AU - Schrauwen, Eefje

AU - Pas, Suzan

AU - Amerongen, Geert

AU - Rimmelzwaan, Guus

AU - Osterhaus, Ab

PY - 2008

Y1 - 2008

N2 - For the development of feline immunodeficiency virus (FIV) vaccines mostly structural proteins have been evaluated for their capacity to induce protective immunity. In the present study, subunit vaccines containing recombinant FIV accessory proteins Rev and OrfA were evaluated in cats. Cats were vaccinated repeatedly with these proteins, adjuvanted with immune stimulating complexes (ISCOMs). In addition, cats were vaccinated with bacterially expressed fragments spanning the entire FIV envelope protein, either atone or in combination with the regulatory proteins. Subsequently, the cats were challenged with a homologous FIV strain to assess the level of protective immunity achieved with the respective vaccination regimens. Although the vaccines proved to be immunogenic, vaccinated cats were not protected from infection with FIV. (C) 2008 Elsevier Ltd. All rights reserved.

AB - For the development of feline immunodeficiency virus (FIV) vaccines mostly structural proteins have been evaluated for their capacity to induce protective immunity. In the present study, subunit vaccines containing recombinant FIV accessory proteins Rev and OrfA were evaluated in cats. Cats were vaccinated repeatedly with these proteins, adjuvanted with immune stimulating complexes (ISCOMs). In addition, cats were vaccinated with bacterially expressed fragments spanning the entire FIV envelope protein, either atone or in combination with the regulatory proteins. Subsequently, the cats were challenged with a homologous FIV strain to assess the level of protective immunity achieved with the respective vaccination regimens. Although the vaccines proved to be immunogenic, vaccinated cats were not protected from infection with FIV. (C) 2008 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.vaccine.2008.03.023

DO - 10.1016/j.vaccine.2008.03.023

M3 - Article

C2 - 18430494

SN - 0264-410X

VL - 26

SP - 2553

EP - 2561

JO - Vaccine

JF - Vaccine

IS - 21

ER -